WEKO3
アイテム
進行胃癌患者におけるSPIRITS試験での適格・不適格基準の臨床的意義
http://hdl.handle.net/10232/00032558
http://hdl.handle.net/10232/00032558cea3a712-8b47-4fb6-97ab-857ba6387259
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
Digest_佐竹_霜一_ISK702_2023 (826 KB)
|
|
|
|
Abstract_佐竹_霜一_4518810164_2023 (116.9 kB)
|
|
|
|
Result_SATAKE_Souich_isk_702 (116.5 kB)
|
|
|
|
Comments_SATAKE_Souich_isk_702 (58.7 kB)
|
|
| Item type | 学位論文 / Thesis or Dissertation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2023-06-05 | |||||
| タイトル | ||||||
| タイトル | Clinical Significance of Eligibility Criteria Determined by the SPIRITS Trial in Patients with Advanced Gastric Cancer | |||||
| タイトル言語 | en | |||||
| タイトル | ||||||
| タイトル | 進行胃癌患者におけるSPIRITS試験での適格・不適格基準の臨床的意義 | |||||
| タイトル言語 | ja | |||||
| 著者 |
佐竹, 霜一
× 佐竹, 霜一 |
|||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 主題言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Clinical trials | |||||
| キーワード | ||||||
| 主題言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Eligibility criteria | |||||
| キーワード | ||||||
| 主題言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Chemotherapy | |||||
| キーワード | ||||||
| 主題言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Prognosis | |||||
| キーワード | ||||||
| 主題言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Advanced gastric cancer | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_46ec | |||||
| 資源タイプ | thesis | |||||
| 要約 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Introduction: This study aimed to assess the clinical significance of eligibility criteria determined by phase 3 clinical trials in the clinical practice of patients with advanced gastric cancer who underwent chemotherapy. Methods: Patients with stage IV gastric cancer who received chemotherapy between February 2002 and December 2021 were retrospectively enrolled and divided into two groups (the eligible vs. ineligible group) based on eligibility criteria determined by the SPIRITS (S-1 vs. S-1 plus cisplatin) trial. Results: Among the 207 patients, 103 (49.8%) and 104 (50.2%) patients were classified into eligible and ineligible groups, respectively. Eligibility criteria were significantly correlated with age, the first-line regimen of chemotherapy, the presence or absence of conversion surgery, and tumor response to the first-line chemotherapy (all p < 0.01). The eligible group had a significantly higher induction of post-progression chemotherapy after first- and second-line chemotherapy than did the ineligible group (all p < 0.01). The ineligible group had significantly poorer prognoses than the eligible group (p < 0.0001). Multivariate analysis showed that peritoneal dissemination, tumor response, conversion surgery, and eligibility criteria were independent prognostic factors (all p < 0.05). Conclusion: Eligibility criteria determined by the SPIRITS trial may have clinical utility for predicting tumor response, the induction of conversion surgery, and prognosis in patients with advanced gastric cancer who underwent chemotherapy. Souichi Satake, Takaaki Arigami, Daisuke Matsushita, Keishi Okubo, Masataka Shimonosono, Ken Sasaki, Yusuke Tsuruda, Kan Tanabe, Shinichiro Mori, Shigehiro Yanagita, Yoshikazu Uenosono, Akihiro Nakajo, Hiroshi Kurahara, Takao Ohtsuka Clinical Significance of Eligibility Criteria Determined by the SPIRITS Trial in Patients with Advanced Gastric Cancer Oncology (2023) 101 (1): 12–21. |
|||||
| 内容記述言語 | en | |||||
| 要約 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | This is the peer-reviewed but unedited manuscript version of the following article: [Oncology (2023) 101 (1): 12–21. (DOI: 10.1159/000527114)]. The final, published version is available at http://karger.com/?doi=10.1159/000527114]. | |||||
| 内容記述言語 | en | |||||
| 作成日 | ||||||
| 日付 | 2023-05-11 | |||||
| 日付タイプ | Collected | |||||
| NDC | ||||||
| 主題Scheme | NDC | |||||
| 主題 | 490 | |||||
| ファイル（説明） | ||||||
| 内容記述 | 博士論文要約, 博士論文要旨, 最終試験結果の要旨, 論文審査の要旨 | |||||
| 公開者・出版者 | ||||||
| 出版者 | Karger | |||||
| 出版者言語 | en | |||||
| 公開者・出版者 | ||||||
| 出版者 | 鹿児島大学 | |||||
| 出版者言語 | ja | |||||
| 備考 | ||||||
| 備考言語 | ja | |||||
| 備考 | 【指導教員:大塚隆生】要約公表の理由: 出版社版が公開不可のため | |||||
| date.appl | ||||||
| appl | 【学位申請日】2023-03-01 | |||||
| 学位名 | ||||||
| 学位名の言語 | ja | |||||
| 学位名 | 博士(医学) | |||||
| 学位名 | ||||||
| 学位名の言語 | en | |||||
| 学位名 | Doctor of Philosophy in Medical Science | |||||
| 学位授与機関名 | ||||||
| 学位授与機関識別子Scheme | kakenhi | |||||
| 学位授与機関識別子 | 17701 | |||||
| 学位授与機関名の言語 | ja | |||||
| 学位授与機関名 | 鹿児島大学 | |||||
| 学位授与年月日 | ||||||
| 学位授与年月日 | 2023-05-25 | |||||
| 学位授与番号 | ||||||
| 学位授与番号 | 甲総研第702号 | |||||
